Risk factor
Low price volatility
Profitability factor
Greatly undervalued vs peers
About
Grape King Bio Ltd. is a Taiwanese enterprise specializing in the production and distribution of a diverse array of health-focused items, encompassing pharmaceuticals, traditional remedies, nourishing beverages, and dietary supplements. Its market presence spans Taiwan, mainland China, and various international regions. The company engages with customers through multiple operational avenues, including multi-level marketing channels, conventional distribution networks, and a significant original design and equipment manufacturing (ODM/OEM) division. Among its extensive product range are various mushroom mycelium derivatives, notably ganoderma lucidum, agaricus blazei, antrodia cinnamomea, cordyceps sinensis, and coriolus versicolor. Additionally, it formulates and supplies probiotics featuring strains like enterococcus, bifidobacterium, lactobacillus, pediococcus, streptococcus, saccharomyces, and clostridium, alongside a selection of enzyme products. Beyond its own brand, Grape King Bio offers comprehensive contract services, such as original equipment manufacturing (OEM), original design manufacturing (ODM), custom formulation development, dedicated research and development support, and the provision of raw materials. Established in 1969, the firm maintains its corporate headquarters in Taoyuan City, Taiwan.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA, undervalue
Target Price
The average target price of 1707.TW is 138 and suggests 73.6% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in